Orlistat
Orlistat Price range: $ 59,00 through $ 455,00
Back to products
P-Force Fort
P-Force Fort Price range: $ 56,00 through $ 245,00

Oxytrol

Price range: $ 49,00 through $ 438,00

Oxytrol is an effective transdermal patch designed to help manage the symptoms of an overactive bladder. It provides consistent relief from the frequent, sudden urges to urinate and the accidental leaks often associated with urinary incontinence. The active ingredient, oxybutynin, works by relaxing the bladder muscles to help increase the volume of fluid the bladder can hold. Each discreet patch is engineered for long-lasting wear, delivering a steady dose of medication through the skin for up to four days. By utilizing Oxytrol, you can regain control and return to your daily activities with greater confidence and comfort.

Active substance: Oxybutynin
SKU: Oxytrol Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Oxytrol belongs to a class of medications known as anticholinergic agents and urinary antispasmodics. It delivers oxybutynin transdermally through a matrix patch applied directly to intact skin.

This continuous drug delivery system is prescribed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Prescriptions and dispensing are managed in accordance with applicable federal and state regulations.

Clinical Overview

Parameter Details
Drug name Oxytrol
Active ingredient (INN) Oxybutynin
Therapeutic class Anticholinergic / Urinary Antispasmodic
Dosage form Transdermal system (patch)
Route of administration Transdermal
Primary purpose Treatment of overactive bladder symptoms
Prescription status Prescription (Rx)

How the drug works

Oxybutynin acts as a competitive antagonist at muscarinic acetylcholine receptors, particularly the M1 and M3 receptor subtypes located on the detrusor muscle of the bladder. By blocking the action of acetylcholine on these smooth muscle receptors, oxybutynin decreases bladder smooth muscle tone, reduces involuntary detrusor contractions, and increases initial bladder capacity. The transdermal route avoids the presystemic hepatic first-pass metabolism associated with oral administration, resulting in a lower concentration of the active metabolite N-desethyloxybutynin, which is frequently associated with systemic anticholinergic side effects such as severe dry mouth and constipation.

What it’s used for

Oxytrol is indicated for the treatment of overactive bladder in patients experiencing symptoms of urge urinary incontinence, urinary urgency, and increased urinary frequency. Overactive bladder occurs when the detrusor muscle contracts involuntarily during the bladder filling phase. Oxytrol helps stabilize the detrusor muscle, thereby reducing the sudden, strong urges to urinate and minimizing involuntary leakage episodes. It is important to note that Oxytrol is specific to detrusor overactivity and is not indicated for stress urinary incontinence, which stems from pelvic floor muscle weakness rather than detrusor spasms.

Dosing schedule

The standard dosage for Oxytrol is one 3.9 mg/day transdermal system applied twice weekly (every 3 to 4 days). Each patch should be applied to clean, dry, smooth skin on the abdomen, hip, or buttocks. Application sites should be rotated with each new patch, avoiding application to the exact same site within seven days. Skin should be free of lotions, oils, powders, or lesions prior to application. The system should be pressed firmly in place with the palm of the hand for at least 10 seconds to ensure proper adhesion. Used patches should be folded in half with the adhesive sides together and disposed of safely out of reach of children and pets.

How it’s absorbed and eliminated

Following application of the transdermal system, oxybutynin is continuously absorbed through intact skin into the systemic circulation over a 3- to 4-day interval. Steady-state plasma concentrations are achieved during the second application. Transdermal administration bypasses initial gastrointestinal and hepatic first-pass metabolism, yielding a significantly lower ratio of the metabolite N-desethyloxybutynin to parent oxybutynin compared to oral formulations. Oxybutynin is extensively metabolized by the liver, primarily via the cytochrome P450 enzyme system, specifically CYP3A4. Elimination occurs mainly through metabolic pathways, with plasma concentrations declining after patch removal consistent with transdermal elimination dynamics.

Patient Care and Safety Guidelines

Compatibility with other medicines

Concomitant administration of Oxytrol with other anticholinergic medications (such as atropine, diphenhydramine, or other bladder antispasmodics) may increase the frequency or severity of anticholinergic side effects, including dry mouth, constipation, urinary retention, and cognitive impairment. Potent inhibitors of the CYP3A4 enzyme system (such as ketoconazole, itraconazole, or erythromycin) may alter oxybutynin metabolism, potentially elevating plasma concentrations of the drug. Additionally, drugs that affect gastrointestinal motility or central nervous system depressants should be evaluated carefully by a healthcare provider prior to co-administration with transdermal oxybutynin.

Adverse reactions

Application site reactions are the most frequently reported adverse effects associated with transdermal oxybutynin, including local erythema, pruritus, and mild skin irritation. Systemic anticholinergic adverse events may also occur, though typically at a lower incidence than with oral formulations. Common systemic side effects include dry mouth, constipation, somnolence, blurred vision, and dry eyes. Less common reactions include urinary hesitation, dysuria, dizziness, and headache. If skin irritation becomes severe or persists beyond patch removal, patients should discontinue use at that site and consult a healthcare professional.

Important precautions

Oxytrol is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma, as well as those with known hypersensitivity to oxybutynin or any component of the transdermal system. Caution is advised when administering to patients with clinically significant bladder outlet obstruction, gastrointestinal obstructive disorders, or severe ulcerative colitis. Central nervous system effects, such as drowsiness or dizziness, may impair mental or physical abilities required for operating machinery or driving. Geriatric patients may exhibit increased sensitivity to anticholinergic effects, warranting careful monitoring during therapy initiation and dose evaluation.

Practical tips

Patients using Oxytrol can continue routine daily activities, including showering, bathing, and swimming, as the patch is designed to remain intact during contact with water. However, excessive rubbing or scrubbing around the application site should be avoided. If a patch falls off prematurely, it should be discarded, and a new patch should be applied to a fresh skin site, continuing with the original application schedule. Patients should avoid exposing the application site to direct heat sources such as heating pads or prolonged sunlight, as warmth can alter transdermal absorption rates.

If you skip a dose

If a patch application is delayed beyond the scheduled 3- to 4-day interval, apply a new patch as soon as remembered to a clean, unirritated area of skin. Following application of the new patch, resume the regular twice-weekly schedule from that day forward. Do not apply multiple patches simultaneously to make up for a missed application, as applying extra patches increases the risk of systemic anticholinergic toxicity.

Food and alcohol interactions

Transdermal administration of oxybutynin is not affected by food intake, allowing patches to be applied regardless of meal times. Alcohol consumption may exacerbate central nervous system side effects associated with anticholinergic therapy, such as drowsiness, sedation, dizziness, or impaired coordination. Patients are advised to exercise caution regarding alcohol use while undergoing treatment with Oxytrol.

Red flags

Immediate medical evaluation is required if patients experience signs of a severe allergic reaction, such as angioedema (swelling of the face, lips, tongue, or throat) or difficulty breathing. Medical attention must also be sought promptly if patients develop acute urinary retention (inability to empty the bladder), severe abdominal pain, signs of heat stroke due to decreased sweating, or sudden vision changes accompanied by eye pain, which may indicate acute narrow-angle glaucoma.

Severe Adverse Event Immediate Action Required
Swelling of face, lips, tongue, or throat Seek emergency medical assistance immediately.
Inability to urinate (urinary retention) Discontinue patch and contact a healthcare provider urgently.
Sudden eye pain or rapid vision changes Obtain immediate ophthalmologic or emergency evaluation.
Severe skin blistering or severe localized rash Remove patch, wash area, and seek medical assessment.
Confusion, severe dizziness, or hallucinations Contact a physician promptly and avoid hazardous activities.

Frequently Asked Questions

How does the transdermal patch compare to oral oxybutynin regarding dry mouth?

Transdermal oxybutynin bypasses initial hepatic first-pass metabolism, which significantly lowers the formation of the metabolite N-desethyloxybutynin. This primary metabolite is predominantly responsible for salivary gland inhibition. Clinical evaluations demonstrate that transdermal administration results in a lower incidence of severe dry mouth compared to standard oral oxybutynin formulations.

Can the Oxytrol patch be worn during physical exercise and swimming?

Yes, the transdermal system is engineered to maintain adhesion during routine exposure to water, including bathing, showering, and swimming. Exercise does not generally disrupt patch adherence, provided the application site was clean, dry, and free of oils or lotions prior to application. However, patients should refrain from vigorous scrubbing directly over the patch area.

What should be done if the skin under the patch becomes red or itchy?

Mild erythema and itching at the application site are common and often resolve after patch removal. To minimize local irritation, application sites must be rotated so that the same skin area is not used more than once every seven days. If redness persists, forms blisters, or causes severe discomfort, the patch should be removed, and medical advice should be sought.

Is it safe to drive or operate machinery while using Oxytrol?

Anticholinergic medications can cause central nervous system effects such as somnolence, dizziness, and blurred vision. Patients should evaluate their individual response to Oxytrol before engaging in activities that demand mental alertness or clear vision, such as driving an automobile or operating hazardous machinery.

What happens if the patch falls off before the scheduled replacement day?

If a patch detaches prematurely, it should be discarded. A new transdermal system should be applied immediately to a different, clean skin site on the abdomen, hip, or buttocks. The patient should then maintain the original dosing schedule originally established for patch replacement.

In accordance with FDA requirements.

Information on this page is for reference and does not replace an assessment by a licensed healthcare professional.

Additional information
Dosage

5mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία